Value202020212022202320242025TTMCash from investing activities-5.03 M-5.8 M-3.32 M5.83 M-215 K-634 K-434 KCash from financing activities1.33 M70.52 M94.98 M5.39 M50.45 M95.16 M85.22 MFree cash flow-92.42 M-15.91 M-49.07 M-86.07 M-58.7 M-65.93 M-58.77 M
Precision BioSciences, Inc. - Common Stock
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.